Solos Endoscopy, Inc. Makes Significant Design Improvement To Its MammoView(TM) Ductoscope
BOSTON, Dec. 18 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company has made a significant design improvement to its MammoView™ ductoscope. In January 2010, the company will introduce a new ductoscope replacing the stainless steel tip with a much stronger braided polyimide tip.
"We are very pleased with the improvements we have made to our ductoscope. One of the major difficulties in dealing with micro-endoscopes in general is increasing durability without increasing the outer diameter. We believe that the braided polyimide tip is superior in durability to both the stainless steel and wire-wrapped tip, while not only maintaining the same outside dimensions but also the same image quality," stated Bob Segersten, President of Solos Endoscopy, Inc.
The MammoView™ instrument line is designed exclusively for breast endoscopy. The MammoView™ system produces clear video images allowing for direct observation of tremendously confined spaces such as the lining of the mammary ducts. The system allows physicians to perform a variety of procedures with minimal or no discomfort for patients.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market breakthrough instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
SOURCE Solos Endoscopy, Inc.